United Therapeutics (NASDAQ:UTHR) has been assigned a $118.00 price target by analysts at Cowen in a research note issued to investors on Friday, TipRanks reports. The firm currently has a “hold” rating on the biotechnology company’s stock. Cowen’s price objective would suggest a potential upside of 46.24% from the stock’s current price.
Other equities analysts have also issued reports about the stock. Credit Suisse Group upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $98.00 to $101.00 in a report on Monday, July 1st. Jefferies Financial Group upgraded shares of United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 target price for the company in a report on Thursday, August 1st. BidaskClub lowered shares of United Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 target price for the company. in a research report on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH raised shares of United Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $103.00 to $106.00 in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $121.73.
UTHR traded up $0.87 on Friday, hitting $80.69. The company had a trading volume of 502,186 shares, compared to its average volume of 379,197. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.62 and a quick ratio of 4.41. United Therapeutics has a 52-week low of $74.31 and a 52-week high of $129.59. The stock has a fifty day simple moving average of $80.82 and a 200-day simple moving average of $92.84. The firm has a market capitalization of $3.50 billion, a P/E ratio of 6.03 and a beta of 0.92.
In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $76.11, for a total value of $285,412.50. Following the sale, the director now owns 3,750 shares in the company, valued at approximately $285,412.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard Giltner sold 5,000 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $79.05, for a total transaction of $395,250.00. Following the completion of the sale, the director now owns 5,000 shares in the company, valued at approximately $395,250. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Atria Investments LLC bought a new position in shares of United Therapeutics during the second quarter valued at approximately $391,000. Natixis lifted its position in United Therapeutics by 80.3% during the second quarter. Natixis now owns 67,758 shares of the biotechnology company’s stock valued at $5,289,000 after acquiring an additional 30,178 shares during the last quarter. Krensavage Asset Management LLC lifted its position in United Therapeutics by 8.9% during the second quarter. Krensavage Asset Management LLC now owns 550,299 shares of the biotechnology company’s stock valued at $42,956,000 after acquiring an additional 45,000 shares during the last quarter. Magnetar Financial LLC purchased a new stake in United Therapeutics during the second quarter valued at approximately $204,000. Finally, Royal Bank of Canada lifted its position in United Therapeutics by 13.1% during the second quarter. Royal Bank of Canada now owns 36,115 shares of the biotechnology company’s stock valued at $2,818,000 after acquiring an additional 4,190 shares during the last quarter. Institutional investors and hedge funds own 94.16% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Further Reading: Exchange-Traded Funds (ETFs)
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.